These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 19378679)

  • 1. Incidence of stent thrombosis in patients with drug eluting stents and short-term dual antiplatelet therapy.
    Steinwender C; Hartenthaler B; Lambert T; Kypta A; Kammler J; Hönig S; Hofmann R; Kerschner K; Leisch F
    EuroIntervention; 2009 Mar; 4(5):593-9. PubMed ID: 19378679
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Three-month dual antiplatelet therapy after implantation of zotarolimus-eluting stents: the DATE (Duration of Dual Antiplatelet Therapy AfterImplantation of Endeavor Stent) registry.
    Hahn JY; Song YB; Choi JH; Choi SH; Lee SY; Park HS; Hur SH; Lee S; Han KR; Rha SW; Cho BR; Park JS; Yoon J; Lim DS; Lee SH; Gwon HC;
    Circ J; 2010 Nov; 74(11):2314-21. PubMed ID: 20938098
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety and efficacy of biodegradable polymer-coated sirolimus-eluting stents in "real-world" practice: 18-month clinical and 9-month angiographic outcomes.
    Han Y; Jing Q; Xu B; Yang L; Liu H; Shang X; Jiang T; Li Z; Zhang H; Li H; Qiu J; Liu Y; Li Y; Chen X; Gao R;
    JACC Cardiovasc Interv; 2009 Apr; 2(4):303-9. PubMed ID: 19463441
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Two-year outcomes after first- or second-generation drug-eluting or bare-metal stent implantation in all-comer patients undergoing percutaneous coronary intervention: a pre-specified analysis from the PRODIGY study (PROlonging Dual Antiplatelet Treatment After Grading stent-induced Intimal hyperplasia studY).
    Valgimigli M; Tebaldi M; Borghesi M; Vranckx P; Campo G; Tumscitz C; Cangiano E; Minarelli M; Scalone A; Cavazza C; Marchesini J; Parrinello G;
    JACC Cardiovasc Interv; 2014 Jan; 7(1):20-8. PubMed ID: 24332420
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Stent thrombosis, clinical events, and influence of prolonged clopidogrel use after placement of drug-eluting stent data from an observational cohort study of drug-eluting versus bare-metal stents.
    Park DW; Yun SC; Lee SW; Kim YH; Lee CW; Hong MK; Cheong SS; Kim JJ; Park SW; Park SJ
    JACC Cardiovasc Interv; 2008 Oct; 1(5):494-503. PubMed ID: 19463351
    [TBL] [Abstract][Full Text] [Related]  

  • 6. What do you do with the antiplatelet agents in patients with drug eluting stents who then receive a mechanical valve?
    Rossi M; Serraino GF; Spadafora A; Renzulli A
    Interact Cardiovasc Thorac Surg; 2012 Jul; 15(1):115-21. PubMed ID: 22457187
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Three vs twelve months of dual antiplatelet therapy after zotarolimus-eluting stents: the OPTIMIZE randomized trial.
    Feres F; Costa RA; Abizaid A; Leon MB; Marin-Neto JA; Botelho RV; King SB; Negoita M; Liu M; de Paula JE; Mangione JA; Meireles GX; Castello HJ; Nicolela EL; Perin MA; Devito FS; Labrunie A; Salvadori D; Gusmão M; Staico R; Costa JR; de Castro JP; Abizaid AS; Bhatt DL;
    JAMA; 2013 Dec; 310(23):2510-22. PubMed ID: 24177257
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The excel stent: a good DES, but can we really stop clopidogrel after 6 months?
    Margolis JR
    JACC Cardiovasc Interv; 2009 Apr; 2(4):310-1. PubMed ID: 19463442
    [No Abstract]   [Full Text] [Related]  

  • 9. The PASEO (PaclitAxel or Sirolimus-Eluting Stent Versus Bare Metal Stent in Primary Angioplasty) Randomized Trial.
    Di Lorenzo E; De Luca G; Sauro R; Varricchio A; Capasso M; Lanzillo T; Manganelli F; Mariello C; Siano F; Pagliuca MR; Stanco G; Rosato G
    JACC Cardiovasc Interv; 2009 Jun; 2(6):515-23. PubMed ID: 19539255
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The unrestricted use of sirolimus- and paclitaxel-eluting stents results in better clinical outcomes during 6-year follow-up than bare-metal stents: an analysis of the RESEARCH (Rapamycin-Eluting Stent Evaluated At Rotterdam Cardiology Hospital) and T-SEARCH (Taxus-Stent Evaluated At Rotterdam Cardiology Hospital) registries.
    Simsek C; Magro M; Boersma E; Onuma Y; Nauta ST; Gaspersz MP; van der Giessen WJ; van Domburg RT; Serruys PW;
    JACC Cardiovasc Interv; 2010 Oct; 3(10):1051-8. PubMed ID: 20965464
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Incidence and predictors of very late (>or=4 years) major cardiac adverse events in the DESIRE (Drug-Eluting Stents in the Real World)-Late registry.
    Costa JR; Sousa A; Moreira AC; Costa RA; Cano M; Maldonado G; Campos C; Carballo M; Pavanello R; Sousa JE
    JACC Cardiovasc Interv; 2010 Jan; 3(1):12-8. PubMed ID: 20129562
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of early versus late clopidogrel discontinuation on stent thrombosis following percutaneous coronary intervention with first- and second-generation drug-eluting stents.
    Loh JP; Torguson R; Pendyala LK; Omar A; Chen F; Satler LF; Pichard AD; Waksman R
    Am J Cardiol; 2014 Jun; 113(12):1968-76. PubMed ID: 24767975
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Drug-eluting stent thrombosis 1,659 days after stent deployment: case report and literature review.
    Al-Dehneh A; Virk H; Alkhouri Y; Hamdan A; Bikkina M
    Tex Heart Inst J; 2010; 37(3):343-6. PubMed ID: 20548819
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Paclitaxel and sirolimus eluting stents versus bare metal stents: long-term risk of stent thrombosis and other outcomes. From the Western Denmark Heart Registry.
    Jensen LO; Tilsted HH; Thayssen P; Kaltoft A; Maeng M; Lassen JF; Hansen KN; Madsen M; Ravkilde J; Johnsen SP; Sørensen HT; Thuesen L
    EuroIntervention; 2010 Apr; 5(8):898-905. PubMed ID: 20542774
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Reduced antiplatelet therapy after drug-eluting stenting: multicenter Janus Flex carbostent implantation with short dual antiplatelet treatment for 2 or 6 months-MATRIX study.
    Cassese S; De Luca G; Villari B; Berti S; Bellone P; Alfieri A; Montinaro A; Quaranta G; Marraccini P; Piscione F;
    Catheter Cardiovasc Interv; 2012 Sep; 80(3):408-16. PubMed ID: 21735531
    [TBL] [Abstract][Full Text] [Related]  

  • 16. 2-year clinical follow-up from the randomized comparison of biolimus-eluting stents with biodegradable polymer and sirolimus-eluting stents with durable polymer in routine clinical practice.
    Klauss V; Serruys PW; Pilgrim T; Buszman P; Linke A; Ischinger T; Eberli F; Corti R; Wijns W; Morice MC; di Mario C; van Geuns RJ; van Es GA; Kalesan B; Wenaweser P; Jüni P; Windecker S
    JACC Cardiovasc Interv; 2011 Aug; 4(8):887-95. PubMed ID: 21851904
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Duration of dual antiplatelet therapy after implantation of the first-generation and second-generation drug-eluting stents.
    Yu X; Chen F; He J; Gao Y; Wu C; Luo Y; Zhang X; Zhang Y; Ren X; Lv S
    Coron Artery Dis; 2013 May; 24(3):217-23. PubMed ID: 23425771
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Incidence, predictors, and outcome of thrombosis after successful implantation of drug-eluting stents.
    Iakovou I; Schmidt T; Bonizzoni E; Ge L; Sangiorgi GM; Stankovic G; Airoldi F; Chieffo A; Montorfano M; Carlino M; Michev I; Corvaja N; Briguori C; Gerckens U; Grube E; Colombo A
    JAMA; 2005 May; 293(17):2126-30. PubMed ID: 15870416
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Acute myocardial infarction related to very late sirolimus-eluting stent thrombosis 6 months after discontinuation of dual antiplatelet therapy.
    Balbi M; Fedele M; Bezante GP; Brunelli C; Barsotti A
    J Cardiovasc Med (Hagerstown); 2011 Nov; 12(11):839-42. PubMed ID: 20216229
    [No Abstract]   [Full Text] [Related]  

  • 20. Improved late clinical safety with zotarolimus-eluting stents compared with paclitaxel-eluting stents in patients with de novo coronary lesions: 3-year follow-up from the ENDEAVOR IV (Randomized Comparison of Zotarolimus- and Paclitaxel-Eluting Stents in Patients With Coronary Artery Disease) trial.
    Leon MB; Nikolsky E; Cutlip DE; Mauri L; Liberman H; Wilson H; Patterson J; Moses J; Kandzari DE;
    JACC Cardiovasc Interv; 2010 Oct; 3(10):1043-50. PubMed ID: 20965463
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.